COMPANY PROFILE

Glyscend

Explore full profile

Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes

Baltimore, United StatesFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Glyscend

Glyscend Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for the treatment of Type 2 Diabetes and obesity. The company operates in the healthcare and pharmaceutical market, targeting patients who are diabetic, overweight, or obese. Glyscend's core product, GLY-200, is designed to mimic the effects of bariatric surgery without the need for invasive procedures. This novel approach aims to provide the metabolic benefits of gastric bypass surgery through an oral pill, making it a less risky and more accessible option for patients. Glyscend generates revenue through the development and potential commercialization of its proprietary therapies, supported by venture capital funding. The company is currently in the clinical trial phase, with its lead candidate, GLY-200, undergoing Phase 2 trials.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Baltimore, United States
Employees: 5
Open positions: None listed
Dealroom signal: 57.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Surgery, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jun 2020	$21M	$82M	Sante Ventures · Helmedix	—
SEEDEquity / VC	Jul 2019	$0	—	Undisclosed	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Glyscend website traffic

Latest recorded traffic for Glyscend is 1.5K monthly website visits, up 525% over the last three months. Glyscend's team declined 37.5% over the past year.

Latest monthly visits1.5K 3-month web change+525% 1-year team growth-37.5%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SWSweetBioBiotech startup revolutionizing healing, starting in oral surgery	Memphis, United States	Operational	12	$5M	$1.1M
VHVirta HealthDelivers treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery	Denver, United States	Operational
OTOrexigen TherapeuticsBiopharmaceutical company focused on the treatment of obesity	San Diego, United States	Acquired
CECelladonBiotechnology company developing molecular therapies for the treatment of heart failure	San Diego, United States	Operational
NMNeuros MedicalDeveloping proprietary neurostimulation therapies for unmet needs to patients worldwide	Willoughby, United States	Operational
EBEiger BioPharmaceuticalsBiopharmaceutical company developing a diverse portfolio of well-characterized drugs for rare diseases	San Carlos, United States	Operational
MNMedCity NewsMedCity News - Healthcare technology news, life science current eventsMedCity News	New York City, United States	Operational
OSObatala SciencesOffers contract research services and research products to laboratories in industry and in academia	New Orleans, United States	Operational